In vitro evaluation of the immune-skewing potential of different candidate building blocks for nanoparticle-based allergen immunotherapy for treatment of allergy

Investigator initiated- Amsterdam university medical centers0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

see above

•There are three categories of subjects for blood donation:
•?Subjects with doctor-diagnosed allergic rhinitis
•?Subjects with doctor-diagnosed non-allergic rhinitis
•?Healthy subjects, defined as not having allergic or non-allergic rhinitis or other inflammatory non-communicable diseases such as rheumatoid arthritis, type 2 diabetes, celiac disease, colitis ulcerosa, Chrohn’s disease, and multiple sclerosis.
•All three categories should meet the following additional criteria:
•Age between 18 and 65.
•Signed informed consent.

•History of AIT (SCIT or SLIT) with any allergen within the past year at the time of blood donation.
•Ongoing AIT (SCIT or SLIT) with any allergen at the time of blood donation.
•Vaccination within one week before blood donation.
•Immunosuppressive or biological medication (e.g. IL-5, anti-IgE therapy) within the last six months prior to blood donation.
•Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs.
•Active malignancies or any malignant disease during the previous 5 years.
•Active inflammation or infection at the time of blood donation.
•Use of systemic steroids within 4 weeks before the blood donation.
•Treatment with systemic and local ß-blockers.
•Subjects who are students or employees of the institution or 1st grade relatives or partners of the investigators.

发起方

Investigator initiated- Amsterdam university medical centers